Phase II Clinical Study of Radium-223 Chloride (BAY 88-8223) in Japanese Patients With Symptomatic Castration-Resistant Prostate Cancer (CRPC) With Bone Metastases

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2016年 / 14卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：14 / 15
页数：2
相关论文
共 50 条
  • [41] Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases
    Kapoor, Anil
    Wong, Nathan C.
    Wang, Yuding
    Mukherjee, Som
    Hotte, Sebastien
    Dayes, Ian
    Lukka, Himu
    ASIAN JOURNAL OF ANDROLOGY, 2020, 22 (04) : 437 - 438
  • [42] Phase I pharmacokinetic (PK) and biodistribution study of radium-223 chloride in patients with castration resistant prostate cancer (CRPC) metastatic to bone.
    Carrasquillo, J. A.
    O'Donoghue, J. A.
    Pandit-Taskar, N.
    Rathkopf, D. E.
    Aksnes, A.
    Viner, C. L.
    Hong, C. T.
    Larson, S. M.
    Scher, H. I.
    Morris, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [43] Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases.
    Nilsson, Sten
    Sartor, A. Oliver
    Bruland, Oyvind S.
    Fang, Fang
    Aksnes, Anne-Kirsti
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] Efficacy of Combination Therapy With Radium-223 and Enzalutamide in Castration-resistant Prostate Cancer With Bone Metastases
    Wakita, Naoto
    Hara, Takuto
    Suzuki, Kotaro
    Terakawa, Tomoaki
    Teishima, Jun
    Nakano, Yuzo
    Miyake, Hideaki
    ANTICANCER RESEARCH, 2024, 44 (06) : 2627 - 2635
  • [45] Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases
    Yamamoto, Yoshiyuki
    Okuda, Yohei
    Kanaki, Tomohiro
    Tanaka, Ryo
    Nagahara, Akira
    Nakai, Yasutomo
    Nakayama, Masashi
    Kakimoto, Ken-ichi
    Nishimura, Kazuo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (01) : 192 - 198
  • [46] Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with radium-223
    Parker, C.
    O'Bryan-Tear, C. G.
    Bolstad, B.
    Lokna, A.
    Nilsson, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [47] Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases
    Yoshiyuki Yamamoto
    Yohei Okuda
    Tomohiro Kanaki
    Ryo Tanaka
    Akira Nagahara
    Yasutomo Nakai
    Masashi Nakayama
    Ken-ichi Kakimoto
    Kazuo Nishimura
    International Journal of Clinical Oncology, 2021, 26 : 192 - 198
  • [48] Hematologic Safety Profile of Radium-223 Dichloride (Ra-223) From the Phase 3 ALSYMPCA Trial in Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastases
    Widmark, A.
    Helle, S. I.
    James, N.
    Larsson, A.
    Staudacher, K.
    Haugen, I.
    Garcia-Vargas, J.
    Nilsson, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S189 - S190
  • [49] Administration of radium-223 and the prognosis in Japanese bone metastatic castration-resistant prostate cancer patients: A large database study
    Kawahara, Takashi
    Miyoshi, Yasuhide
    Ninomiya, Sahoko
    Sato, Motoki
    Takeshima, Teppei
    Hasumi, Hisashi
    Makiyama, Kazuhide
    Uemura, Hiroji
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (09) : 1079 - 1084
  • [50] Radium-223 Chloride Safety and Use of External Beam Radiation Therapy (EBRT) in the Phase HI Randomized Trial (ALSYMPCA) in Patients With Castration-resistant Prostate Cancer (CRPC) and Bone Metastases
    Sandler, H. M.
    Nilsson, S.
    Parker, C.
    Garcia-Vargas, J.
    Staudacher, K.
    Hoskin, P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S3 - S4
12345